The Application of JAK Inhibitors in the Peri-transplantation Period of Hematopoietic Stem Cell Transplantation for Myelofibrosis

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Mar 18

PMID 38494551

Authors

Zerong Wang

Xuelian Jin

Jiajia Zeng

Zilin Xiong

Xinchuan Chen

Affiliations

Soon will be listed here.

Abstract

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients' symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.

References

Kroger N, Deeg J, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T . Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015; 29(11):2126-33. DOI: 10.1038/leu.2015.233. View

Choi J, Cooper M, Alahmari B, Ritchey J, Collins L, Holt M . Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014; 9(10):e109799. PMC: 4188578. DOI: 10.1371/journal.pone.0109799. View

Verstovsek S, Mesa R, Gotlib J, Gupta V, Dipersio J, Catalano J . Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017; 10(1):55. PMC: 5322633. DOI: 10.1186/s13045-017-0417-z. View

Hernandez-Boluda J, Czerw T . Transplantation algorithm for myelofibrosis in 2022 and beyond. Best Pract Res Clin Haematol. 2022; 35(2):101369. DOI: 10.1016/j.beha.2022.101369. View

Elli E, Barate C, Mendicino F, Palandri F, Palumbo G . Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. Front Oncol. 2019; 9:1186. PMC: 6854013. DOI: 10.3389/fonc.2019.01186. View

Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X . The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020; 80:106210. DOI: 10.1016/j.intimp.2020.106210. View

Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz D . JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017; 77(5):521-546. PMC: 7102286. DOI: 10.1007/s40265-017-0701-9. View

Hammaren H, Virtanen A, Raivola J, Silvennoinen O . The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2018; 118:48-63. DOI: 10.1016/j.cyto.2018.03.041. View

Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q . Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023; 8(1):204. PMC: 10196327. DOI: 10.1038/s41392-023-01468-7. View

10.

Staerk J, Constantinescu S . The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. JAKSTAT. 2013; 1(3):184-90. PMC: 3670242. DOI: 10.4161/jkst.22071. View

11.

Fasouli E, Katsantoni E . JAK-STAT in Early Hematopoiesis and Leukemia. Front Cell Dev Biol. 2021; 9:669363. PMC: 8160090. DOI: 10.3389/fcell.2021.669363. View

12.

OShea J, Schwartz D, Villarino A, Gadina M, McInnes I, Laurence A . The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015; 66:311-28. PMC: 5634336. DOI: 10.1146/annurev-med-051113-024537. View

13.

Abboud R, Choi J, Ruminski P, Schroeder M, Kim S, Abboud C . Insights into the role of the JAK/STAT signaling pathway in graft--host disease. Ther Adv Hematol. 2020; 11:2040620720914489. PMC: 7268158. DOI: 10.1177/2040620720914489. View

14.

Marsella R, Doerr K, Gonzales A, Rosenkrantz W, Schissler J, White A . Oclacitinib 10 years later: lessons learned and directions for the future. J Am Vet Med Assoc. 2023; 261(S1):S36-S47. DOI: 10.2460/javma.22.12.0570. View

15.

Park H, Oh K, Garmaa N, Seo M, Byoun O, Lee H . CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway. Transplantation. 2010; 90(8):825-35. DOI: 10.1097/TP.0b013e3181f24e59. View

16.

Okiyama N, Furumoto Y, Villarroel V, Linton J, Tsai W, Gutermuth J . Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J Invest Dermatol. 2013; 134(4):992-1000. PMC: 3961527. DOI: 10.1038/jid.2013.476. View

17.

Deisseroth A, Kaminskas E, Grillo J, Chen W, Saber H, Lu H . U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res. 2012; 18(12):3212-7. DOI: 10.1158/1078-0432.CCR-12-0653. View

18.

Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham L . FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Oncologist. 2020; 25(2):e328-e334. PMC: 7011641. DOI: 10.1634/theoncologist.2019-0627. View

19.

Pemmaraju N, Bose P, Rampal R, Gerds A, Fleischman A, Verstovsek S . Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023; 64(6):1063-1081. DOI: 10.1080/10428194.2023.2196593. View

20.

Harrison C, Vannucchi A, Kiladjian J, Al-Ali H, Gisslinger H, Knoops L . Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30(8):1701-7. PMC: 5399157. DOI: 10.1038/leu.2016.148. View